Mariko Eguchi

Profesor

Ehime University Graduate School of Medicine
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Introduction DUX4 is rearranged and overexpressed in a subgroup of acute lymphoblastic leukemia (ALL) with B‐precursor phenotype, with a favorable outcome. Even though characteristic gene expression signature as well as surface expression of CD2/CD371 could be a hallmark of DUX4 ‐rearranged ALL, actual detection of DUX4 rearrangement is, however, largely dependent on whole transcriptome analysis due to the highly repetitive nature of DUX4 gene loci and insertion as the main mechanism of fusion gene formation. Methods Polymerase chain reactions (PCRs) with several combinations of multiplex primers located on DUX4 and IGH gene loci were used for the detection of DUX4::IGH , which represents more than 90% of DUX4 fusion. Results DUX4::IGH fusion was successfully detected in three out of 50 ALL cases analyzed by standard PCR, and these positive cases showed variable insertion of DUX4 into the IGH locus. In all patients, sequences of unknown origin were observed at the junction of DUX4 and IGH sequences, indicating the role of the V(D)J recombination mechanism in fusion gene formation. Although DUX4 is tandemly repeated at its locus, only a single copy of the DUX4 sequence was detected at the IGH locus in two of the three DUX4 ‐rearranged ALL cases. As previously reported, both CD2 and CD371 were positive in all cases with DUX4 :: IGH fusion, suggesting that the combination of CD2 and CD371 could be a more reliable marker for detecting the presence of this fusion. Conclusions Identification of DUX4 :: IGH fusion in ALL could be possible more easily by a simple multiplex PCR strategy.

Year:

2025

Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. γδ T-ALL diagnosed in children under 3 years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer–promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High-throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by poly(ADP-ribose) polymerase inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric γδ T-ALL. Significance: Patients with acute lymphoblastic leukemia expressing the gamma delta T-cell receptor under 3 years old or measurable residual disease ≥1% at end of induction showed dismal outcomes and should be classified as having high-risk disease. The STAG2/LMO2 subtype was enriched in this very young age group. STAG2 inactivation may perturb chromatin conformation and cell differentiation and confer vulnerability to poly(ADP-ribose) polymerase inhibition.

Year:

2024

Year:

2022

Collaborators (30)

Shondra Pruett-Miller

Associate Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Chi Kong Li

Professor

The Chinese University of Hong Kong (CUHK)

HONG KONG
View details

Martin Schrappe

-

GERMANY
View details

riccardo masetti

Assistant Professor

University of Bologna

ITALY
View details

Kjeld Schmiegelow

-

DENMARK
View details

Hanne Vibeke Hansen Marquart

Chief Physician; MD, PhD, Clinical Associate Professor

Copenhagen University Hospital

DENMARK
View details

Allen Eng Juh Yeoh

National University of Singapore (NUS)

SINGAPORE
View details

Atsushi Manabe

Professor

Hokkaido University

JAPAN
View details

Gabriele Escherich

-

GERMANY
View details

Valentino Conter

-

ITALY
View details

John Choi

The University of Alabama

UNITED STATES
View details

Franco Locatelli

Full Professor of Pediatrics

Catholic University of the Sacred Heart

ITALY
View details

Steven Kornblau

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Junko Takita

教授 / Professor

Kyoto University

JAPAN
View details

Szymon Skoczen

Associated Professor

Uniwersytet Jagiellonski Collegium Medicum

POLAND
View details

Kathryn Roberts

St. Jude Children's Research Hospital

UNITED STATES
View details

David Teachey

Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Daisuke Tomizawa

Head

National Center For Child Health and Development

JAPAN
View details

Cheng Cheng

Professor

St Jude Grade School of Biomedical Sciences

UNITED STATES
View details

Motohiro Kato

-

JAPAN
View details

Takao Deguchi

Head of Division

National Center For Child Health and Development

JAPAN
View details

Ching-Hon Pui

Fahad Nasser Al-Rashid Chair of Leukemia Research

St. Jude Children's Research Hospital

UNITED STATES
View details

Andrew Moore

Associate Professor

University of Queensland

AUSTRALIA
View details

Ilaria Iacobucci

Principal Scientist

St. Jude Children's Research Hospital

UNITED STATES
View details

Masatoshi Takagi

Tokyo Medical and Dental University

JAPAN
View details

Zhaohui Gu

Assistant Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Paul G Thomas

Professor

Fred Hutch Cancer Center

UNITED STATES
View details

Andishe Attarbaschi

Medical University of Vienna

AUSTRIA
View details

Charles Mullighan

Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center

St. Jude Children's Research Hospital

UNITED STATES
View details

Rishi Kotecha

Professor

Telethon Kids Institute

AUSTRALIA
View details